0.2876
price up icon5.43%   0.0148
 
loading
Genprex Inc stock is traded at $0.2876, with a volume of 785.41K. It is up +5.43% in the last 24 hours and down -1.64% over the past month. Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.2728
Open:
$0.2793
24h Volume:
785.41K
Relative Volume:
0.18
Market Cap:
$9.29M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0246
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
-13.84%
1M Performance:
-1.64%
6M Performance:
-72.35%
1Y Performance:
-89.48%
1-Day Range:
Value
$0.27
$0.2951
1-Week Range:
Value
$0.2615
$0.3356
52-Week Range:
Value
$0.215
$3.97

Genprex Inc Stock (GNPX) Company Profile

Name
Name
Genprex Inc
Name
Phone
512-537-7997
Name
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Name
Employee
15
Name
Twitter
@genprex
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
GNPX's Discussions on Twitter

Compare GNPX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GNPX
Genprex Inc
0.2876 9.29M 0 -22.71M -18.24M -11.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Genprex Inc Stock (GNPX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-26-21 Initiated National Securities Buy
Apr-29-19 Initiated Noble Capital Markets Outperform

Genprex Inc Stock (GNPX) Latest News

pulisher
Jun 05, 2025

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Genprex (NASDAQ:GNPX) Shares Down 2.8% – Should You Sell? - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Genprex to Participate at BIO 2025 International Convention - BioSpace

Jun 03, 2025
pulisher
Jun 03, 2025

Genprex to Participate at BIO 2025 International Convention | GN - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Genprex to Participate at BIO 2025 International Convention | GNPX Stock News - GuruFocus

Jun 03, 2025
pulisher
May 29, 2025

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Nasdaq

May 29, 2025
pulisher
May 28, 2025

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting | GNPX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Genprex (GNPX) Reports Promising Preclinical Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus

May 28, 2025
pulisher
May 24, 2025

What Can Genprex Inc (NASDAQ: GNPX) Expect In 2025? - Stocksregister

May 24, 2025
pulisher
May 14, 2025

WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 10, 2025

Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister

May 10, 2025
pulisher
May 08, 2025

Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech

May 08, 2025
pulisher
May 07, 2025

Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister

May 07, 2025
pulisher
May 07, 2025

Genprex Announces Research Agreement for Diabetes Therapy - TipRanks

May 07, 2025
pulisher
May 07, 2025

Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PR Newswire

May 07, 2025
pulisher
May 06, 2025

Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Secures Exclusive Patent License for Reqorsa - TipRanks

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Techn - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma | GNPX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PR Newswire

May 06, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World

May 05, 2025
pulisher
May 02, 2025

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - ADVFN

May 02, 2025
pulisher
May 02, 2025

Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting - SelectScience

May 02, 2025
pulisher
Apr 30, 2025

Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire

Apr 30, 2025
pulisher
Apr 29, 2025

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve

Apr 29, 2025
pulisher
Apr 29, 2025

Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Taking the lead: Genprex Inc (GNPX) - Sete News

Apr 29, 2025
pulisher
Apr 29, 2025

Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus

Apr 29, 2025
pulisher
Apr 28, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia

Apr 28, 2025
pulisher
Apr 28, 2025

Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Signs Exclusive Technology License Agreement with New Yo - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex (GNPX) Secures Exclusive License for Gene Therapy Patent - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Signs Agreement With New York University Langone Health - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Revolutionary Gene Therapy Shows 84% Target Success in Mesothelioma Treatment: Genprex-NYU Partnership - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - The Malaysian Reserve

Apr 28, 2025
pulisher
Apr 27, 2025

Short Interest in Genprex, Inc. (NASDAQ:GNPX) Grows By 487.6% - Defense World

Apr 27, 2025

Genprex Inc Stock (GNPX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Cap:     |  Volume (24h):